Development of a Multi-Biomarker Disease Activity Test for Rheumatoid Arthritis

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Centola, Michael ^a   Cavet, Guy ^b   Shen, Yijing ^b   Ramanujan, Saroja ^b   Knowlton, Nicholas ^a   Swan, Kathryn A ^b   Turner, Mary ^a   Sutton, Chris ^a   Smith, Dustin R ^a   Haney, Douglas J ^b   Chernoff, David ^b   Hesterberg, Lyndal K ^b   Carulli, John P ^c   Taylor, Peter C ^d   Shadick, Nancy A ^e   Weinblatt, Michael E ^e   Curtis, Jeffrey R ^f  

^a OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

^b Crescendo Bioscience Inc   (United States)

^c BIOGEN   (United States)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; MESSENGER RNA;

ARTICLE; BIOINFORMATICS; BLOOD ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DAS28; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE COURSE; FEASIBILITY STUDY; FEMALE; HUMAN; JOINT RADIOGRAPHY; MAJOR CLINICAL STUDY; MALE; MULTI BIOMARKER DISEASE ACTIVITY TEST; PROTEIN MICROARRAY; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; RHEUMATOID ARTHRITIS; SCORING SYSTEM;

ADULT; AGED; ALGORITHMS; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; FEMALE; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; MIDDLE AGED; MODELS, STATISTICAL; ROC CURVE; SEVERITY OF ILLNESS INDEX;

EID: 84876036371     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060635     Document Type: Article

References (49)

1. Bakker MF, Jacobs JW, Verstappen SM, Bijlsma JW (2007) Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility. Ann Rheum Dis 66 Suppl 3: iii56-60. Available:http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=17934098.
2. Verstappen SMM, Jacobs JWG, van der Veen MJ, Heurkens AH, Schenk Y, et al. (2007) Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Annals of the rheumatic diseases 66: 1443-1449. Available:http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2111604&tool=pmcentrez&rendertype=abstract. Accessed 22 July 2011.
3. Mease PJ (2010) Improving the routine management of rheumatoid arthritis: the value of tight control. The Journal of rheumatology 37: 1570-1578. Available:http://www.ncbi.nlm.nih.gov/pubmed/20595287. Accessed 23 July 2012.
4. Smolen JS, Aletaha D, Bijlsma JWJ, Breedveld FC, Boumpas D, et al. (2010) Treating rheumatoid arthritis to target: recommendations of an international task force. Annals of the rheumatic diseases 69: 631-637. Available:http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3015099&tool=pmcentrez&rendertype=abstract. Accessed 24 June 2011.
5. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, et al. (2012) 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis care & research 64: 625-639. Available:http://www.ncbi.nlm.nih.gov/pubmed/22473917. Accessed 15 July 2012.
6. Wells G, Becker J-C, Teng J, Dougados M, Schiff M, et al. (2009) Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Annals of the rheumatic diseases 68: 954-960. Available:http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2674547&tool=pmcentrez&rendertype=abstract. Accessed 18 July 2011.
7. Fransen J, van Riel PLCM (n.d.) The Disease Activity Score and the EULAR response criteria. Clinical and experimental rheumatology 23: S93-9. Available:http://www.ncbi.nlm.nih.gov/pubmed/16273792. Accessed 22 October 2012.
8. Zatarain E, Strand V (2006) Monitoring disease activity of rheumatoid arthritis in clinical practice: contributions from clinical trials. Nature clinical practice Rheumatology 2: 611-618. Available:http://www.ncbi.nlm.nih.gov/pubmed/17075600. Accessed 25 January 2012.
9. Pincus T, Swearingen CJ, Bergman M, Yazici Y (2008) RAPID3 (Routine Assessment of Patient Index Data 3), a rheumatoid arthritis index without formal joint counts for routine care: proposed severity categories compared to disease activity score and clinical disease activity index categories. The Journal of rheumatology 35: 2136-2147. Available:http://www.ncbi.nlm.nih.gov/pubmed/18793006. Accessed 7 November 2012.
10. Uhlig T, Kvien TK, Pincus T (2009) Test-retest reliability of disease activity core set measures and indices in rheumatoid arthritis. Annals of the rheumatic diseases 68: 972-975. Available:http://www.ncbi.nlm.nih.gov/pubmed/18957489. Accessed 22 July 2011.
11. Ranzolin A, Brenol JCT, Bredemeier M, Guarienti J, Rizzatti M, et al. (2009) Association of concomitant fibromyalgia with worse disease activity score in 28 joints, health assessment questionnaire, and short form 36 scores in patients with rheumatoid arthritis. Arthritis and rheumatism 61: 794-800. Available:http://www.ncbi.nlm.nih.gov/pubmed/19479706. Accessed 23 August 2011.
12. Leeb BF, Andel I, Sautner J, Nothnagl T, Rintelen B (2004) The DAS28 in rheumatoid arthritis and fibromyalgia patients. Rheumatology (Oxford, England) 43: 1504-1507. Available:http://www.ncbi.nlm.nih.gov/pubmed/15252215. Accessed 25 January 2012.
13. Marhadour T, Jousse-Joulin S, Chalès G, Grange L, Hacquard C, et al. (2010) Reproducibility of joint swelling assessments in long-lasting rheumatoid arthritis: influence on Disease Activity Score-28 values (SEA-Repro study part I). The Journal of rheumatology 37: 932-937. Available:http://www.ncbi.nlm.nih.gov/pubmed/20360184. Accessed 25 January 2012.
14. Sokka T, Pincus T (2009) Erythrocyte sedimentation rate, C-reactive protein, or rheumatoid factor are normal at presentation in 35%-45% of patients with rheumatoid arthritis seen between 1980 and 2004: analyses from Finland and the United States. J Rheumatol 36: 1387-1390. Available:http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19411389.
15. Rhodes B, Merriman ME, Harrison A, Nissen MJ, Smith M, et al. (2010) A genetic association study of serum acute-phase C-reactive protein levels in rheumatoid arthritis: implications for clinical interpretation. PLoS Med 7: e1000341. Available:http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=20877716.
16. Keenan RT, Swearingen CJ, Yazici Y (2008) Erythrocyte sedimentation rate and C-reactive protein levels are poorly correlated with clinical measures of disease activity in rheumatoid arthritis, systemic lupus erythematosus and osteoarthritis patients. Clin Exp Rheumatol 26: 814-819. Available:http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=19032813.
17. Mease PJ (1998) The potential roles for novel biomarkers in rheumatoid arthritis assessment. Clinical and experimental rheumatology 29: 567-574. Available:http://www.ncbi.nlm.nih.gov/pubmed/21640052. Accessed 18 July 2012.
18. Chambers RE, MacFarlane DG, Whicher JT, Dieppe P a (1983) Serum amyloid-A protein concentration in rheumatoid arthritis and its role in monitoring disease activity. Annals of the rheumatic diseases 42: 665-667. Available:http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1001325&tool=pmcentrez&rendertype=abstract. Accessed 18 July 2012.
19. Klimiuk P a, Sierakowski S, Latosiewicz R, Cylwik JP, Cylwik B, et al. (2002) Soluble adhesion molecules (ICAM-1, VCAM-1, and E-selectin) and vascular endothelial growth factor (VEGF) in patients with distinct variants of rheumatoid synovitis. Annals of the rheumatic diseases 61: 804-809. Available:http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1754213&tool=pmcentrez&rendertype=abstract.
20. Hammer HB, Odegard S, Fagerhol MK, Landewé R, van der Heijde D, et al. (2007) Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inflammation and damage in rheumatoid arthritis. Annals of the rheumatic diseases 66: 1093-1097. Available:http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1954700&tool=pmcentrez&rendertype=abstract. Accessed 18 July 2012.
21. Bakker M, Cavet G, Jacobs J, Bijlsma J, Haney D, et al. (2012) Performance of a Multi-Biomarker Score Measuring Rheumatoid Arthritis Disease Activity in the CAMERA Tight Control Study. Annals of Rheumatic Disease.
22. Curtis JR, van der Helm-van Mil AH, Knevel R, Huizinga TW, Haney DJ, et al. (2012) Validation of a novel multi-biomarker test to assess rheumatoid arthritis disease activity. Arthritis care & research. Available:http://www.ncbi.nlm.nih.gov/pubmed/22736476. Accessed 22 July 2012.
23. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, et al. (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis and rheumatism 31: 315-324. Available:http://www.ncbi.nlm.nih.gov/pubmed/3358796. Accessed 18 July 2012.
24. Iannaccone CK, Lee YC, Cui J, Frits ML, Glass RJ, et al. (2011) Using genetic and clinical data to understand response to disease-modifying anti-rheumatic drug therapy: data from the Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study. Rheumatology (Oxford, England) 50: 40-46. Available:http://www.ncbi.nlm.nih.gov/pubmed/20847201. Accessed 18 July 2012.
25. Karlson EW, Chibnik LB, Cui J, Plenge RM, Glass RJ, et al. (2008) Associations between human leukocyte antigen, PTPN22, CTLA4 genotypes and rheumatoid arthritis phenotypes of autoantibody status, age at diagnosis and erosions in a large cohort study. Annals of the rheumatic diseases 67: 358-363. Available:http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2945890&tool=pmcentrez&rendertype=abstract. Accessed 18 July 2012.
26. Taylor PC, Steuer A, Gruber J, Cosgrove DO, Blomley MJK, et al. (2004) Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis. Arthritis and rheumatism 50: 1107-1116. Available:http://www.ncbi.nlm.nih.gov/pubmed/15077292. Accessed 18 July 2012.
27. Taylor PC, Steuer A, Gruber J, McClinton C, Cosgrove DO, et al. (2006) Ultrasonographic and radiographic results from a two-year controlled trial of immediate or one-year-delayed addition of infliximab to ongoing methotrexate therapy in patients with erosive early rheumatoid arthritis. Arthritis and rheumatism 54: 47-53. Available:http://www.ncbi.nlm.nih.gov/pubmed/16385521. Accessed 18 July 2012.
28. Fleischmann RM, Curtis JR, Hamburger MH, Blumstein H, Swan K, et al. (2010) RA population characteristics in InFoRM, a longitudinal observational study. Ann Rheum Dis 69: 657.
29. Wren JD, Garner HR (2004) Shared relationship analysis: ranking set cohesion and commonalities within a literature-derived relationship network. Bioinformatics (Oxford, England) 20: 191-198. Available:http://bioinformatics.oxfordjournals.org/cgi/doi/10.1093/bioinformatics/btg390. Accessed 18 July 2012.
30. Eastman PS, Manning WC, Qureshi F, Haney D, Cavet G, et al. (2012) Characterization of a multiplex, 12-biomarker test for rheumatoid arthritis. Journal of pharmaceutical and biomedical analysis 70: 415-424. Available:http://www.ncbi.nlm.nih.gov/pubmed/22749821. Accessed 22 October 2012.
31. Todd DJ, Knowlton N, Amato M, Frank MB, Schur PH, et al. (2011) Erroneous augmentation of multiplex assay measurements in patients with rheumatoid arthritis due to heterophilic binding by serum rheumatoid factor. Arthritis and rheumatism 63: 894-903. Available:http://www.ncbi.nlm.nih.gov/pubmed/21305505. Accessed 18 July 2012.
32. Benjamini Y, Hochberg M (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society: Series B (Statistical Methodology) 57: 289-300. Available:http://www.jstor.org/stable/10.2307/2346101. Accessed 19 July 2012.
33. Tibshirani R (1996) Regression shrinkage and selection via the lasso. Journal of the Royal Statistical Society: Series B (Statistical Methodology) 58: 267-288. Available:http://www.jstor.org/stable/10.2307/2346178. Accessed 19 July 2012.
34. Zou H, Hastie T (2005) Regularization and variable selection via the elastic net. Journal of the Royal Statistical Society: Series B (Statistical Methodology) 67: 301-320. Available:http://doi.wiley.com/10.1111/j.1467-9868.2005.00503.x.
35. Hastie T, Tibshirani R, Friedman J (2009) The Elements of Statistical Learning: Data Mining, Inference, and Prediction. New York: Springer. 746 p. Available:http://www.springer.com/statistics/statisticaltheoryandmethods/book/978-0-387-84857-0. Accessed 22 July 2012.
36. Breiman L, Friedman JH (1997) Predicting Multivariate Responses in Multiple Linear Regression. Journal of the Royal Statistical Society: Series B (Statistical Methodology) 59: 3-54. Available:http://onlinelibrary.wiley.com/doi/10.1111/1467-9868.00054/full. Accessed 19 July 2012.
37. Targońska-Stepniak B, Majdan M, Dryglewska M (2008) Leptin serum levels in rheumatoid arthritis patients: relation to disease duration and activity. Rheumatology international 28: 585-591. Available:http://www.ncbi.nlm.nih.gov/pubmed/17968549. Accessed 18 July 2012.
38. Rioja I, Hughes FJ, Sharp CH, Warnock LC, Montgomery DS, et al. (2008) Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor. Arthritis and rheumatism 58: 2257-2267. Available:http://www.ncbi.nlm.nih.gov/pubmed/18668547. Accessed 18 July 2012.
39. Melis L, Vandooren B, Kruithof E, Jacques P, De Vos M, et al. (2010) Systemic levels of IL-23 are strongly associated with disease activity in rheumatoid arthritis but not spondyloarthritis. Annals of the rheumatic diseases 69: 618-623. Available:http://www.ncbi.nlm.nih.gov/pubmed/19196728. Accessed 19 July 2012.
40. Park M-C, Chung SJ, Jung S-J, Park Y-B, Lee S-K (2004) Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis. Scandinavian journal of rheumatology 37: 173-178. Available:http://www.ncbi.nlm.nih.gov/pubmed/18465450. Accessed 19 July 2012.
41. Ehrchen JM, Sunderkötter C, Foell D, Vogl T, Roth J (2009) The endogenous Toll-like receptor 4 agonist S100A8/S100A9 (calprotectin) as innate amplifier of infection, autoimmunity, and cancer. Journal of leukocyte biology 86: 557-566. Available:http://www.ncbi.nlm.nih.gov/pubmed/19451397. Accessed 19 July 2012.
42. Inoue E, Yamanaka H, Hara M, Tomatsu T, Kamatani N (2007) Comparison of Disease Activity Score (DAS)28- erythrocyte sedimentation rate and DAS28- C-reactive protein threshold values. Annals of the rheumatic diseases 66: 407-409. Available:http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1856019&tool=pmcentrez&rendertype=abstract. Accessed 25 January 2012.
43. Lavie F, Miceli-Richard C, Ittah M, Sellam J, Gottenberg J-E, et al. (2007) Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. Annals of the rheumatic diseases 66: 700-703. Available:http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1954605&tool=pmcentrez&rendertype=abstract. Accessed 19 July 2012.
44. Eastman PS, Manning WC, Qureshi F, Haney D, Cavet G, et al. (2012) Characterization of a multiplex, 12-biomarker test for rheumatoid arthritis. Journal of pharmaceutical and biomedical analysis. Available:http://www.ncbi.nlm.nih.gov/pubmed/22749821. Accessed 22 July 2012.
45. Inoue E, Yamanaka H, Hara M, Tomatsu T, Kamatani N (2007) Comparison of Disease Activity Score (DAS)28- erythrocyte sedimentation rate and DAS28- C-reactive protein threshold values. Annals of the rheumatic diseases 66: 407-409. Available:http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1856019&tool=pmcentrez&rendertype=abstract. Accessed 25 January 2012.
46. Paik S, Tang G, Shak S, Kim C, Baker J, et al. (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. Journal of clinical oncology?: official journal of the American Society of Clinical Oncology 24: 3726-3734. Available:http://www.ncbi.nlm.nih.gov/pubmed/16720680. Accessed 13 July 2012.
47. Paik S, Shak S, Tang G, Kim C, Baker J, et al. (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. The New England journal of medicine 351: 2817-2826. Available:http://www.ncbi.nlm.nih.gov/pubmed/15591335.
48. Kolberg JA, Jørgensen T, Gerwien RW, Hamren S, McKenna MP, et al. (2009) Development of a type 2 diabetes risk model from a panel of serum biomarkers from the Inter99 cohort. Diabetes care 32: 1207-1212. Available:http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2699726&tool=pmcentrez&rendertype=abstract. Accessed 13 July 2012.
49. Prevoo ML, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, et al. (1995) Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 38: 44-48. Available:http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=7818570.